🇺🇸 FDA
Pipeline program

LN-145

C-145-03

Phase 2 mab completed

Quick answer

LN-145 for Squamous Cell Carcinoma of the Head and Neck is a Phase 2 program (mab) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Iovance Biotherapeutics B.V.
Indication
Squamous Cell Carcinoma of the Head and Neck
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials